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Vesicular Stomatitis Virus Genomic RNA Persists In Vivo in the
Absence of Viral Replication
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Our previous studies using intranasal inoculation of mice with vesicular stomatitis virus (VSV) vaccine vectors
showed persistence of vector genomic RNA (gRNA) for at least 60 days in lymph nodes in the absence of detectable
infectious virus. Here we show high-level concentration of virus and gRNA in lymph nodes after intramuscular
inoculation of mice with attenuated or single-cycle VSV vectors as well as long-term persistence of gRNA in the
lymph nodes. To determine if the persistence of gRNA was due to ongoing viral replication, we developed a
tagged-primer approach that was critical for detection of VSV mRNA specifically. Our results show that VSV gRNA
persists long-term in the lymph nodes while VSV mRNA is present only transiently. Because VSV transcription is
required for replication, our results indicate that persistence of gRNA does not result from continuing viral
replication. We also performed macrophage depletion studies that are consistent with initial trapping of VSV gRNA
largely in lymph node macrophages and subsequent persistence elsewhere in the lymph node.
Vesicular stomatitis virus (VSV) is a nonsegmented, nega-
tive-strand RNA virus and the prototype of the Rhabdoviridae
family. VSV encodes 5 structural proteins: nucleocapsid pro-
tein (N), phosphoprotein (P), matrix protein (M), the surface
glycoprotein (G), and the RNA-dependent RNA polymerase
(L) (19). Live-attenuated vaccine vectors based on VSV have
been developed and approved for clinical trials. Attenuated
VSV-based vaccine vectors expressing foreign proteins induce
potent immune responses and protect against viral and bacte-
rial disease in several animal models, including nonhuman
primates (9, 13, 15, 16, 17, 21, 25–27, 29, 30). A live-attenuated
VSV-based Ebola virus vaccine vector has also been used in a
person following a possible Ebola virus exposure (http://blogs
.sciencemag.org/scienceinsider/2009/03/researchers-aro.html).
Highly attenuated and single-cycle VSV vectors have been
extensively characterized previously in our laboratory and else-
where (4, 17, 23, 24, 26). The highly attenuated live VSV vector
VSV-CT1 has a truncation of the VSV G cytoplasmic domain
from 29 amino acids to 1 amino acid (32). Compared to re-
combinant wild-type (rwt) vector (rwtVSV), the CT1 vector
grows to approximately 20-fold-lower titers in tissue culture.
The single-cycle VSV vector (VSVG) has a deletion of the
VSV G gene but can be grown in complementing cells express-
ing the VSV G protein (33). This virus can infect cells and
replicate for a single cycle but does not produce infectious
progeny in the absence of complementing VSV G protein.
In previous studies, we found that VSV vaccine vector
genomic RNA (gRNA) persists in the cervical draining lymph
nodes for at least 60 days after intranasal (i.n.) inoculation with
rwtVSV and VSV-CT1 vectors, although infectious virus could
be recovered for only the first 4 days after inoculation (34).
VSV-encoded antigen is also known to persist for at least 6
weeks after acute infection (35). Long-term persistence of live
virus vector replication could present a safety concern. For
example, in rare cases, measles virus replication can persist
long-term and subsequent accumulation of mutations can lead
to subacute sclerosing panencephalitis (2, 5, 31). The purpose
of the current study was to determine if persistence of VSV
gRNA was seen in lymph nodes following intramuscular (i.m.)
inoculation and to examine the mechanism of persistence fol-
lowing i.m. or i.n. inoculation.
Our studies involved developing a quantitative, real-time,
tagged-primer approach with complete specificity for VSV
mRNA. This approach is used to overcome problems with lack
of strand specificity caused by RNA self-priming during the
reverse transcription (RT) step (6). Our studies show that VSV
mRNA is present early after infection but does not persist,
indicating that VSV replication is not ongoing.
Previous studies have demonstrated that macrophages trap
VSV in lymphoid tissues such as the spleen and lymph node (3,
14, 20). Virus injected into the mouse footpad accumulates in
CD169 CD11b major histocompatibility complex (MHC)
II macrophages that comprise 1 to 2% of the mononuclear
cells within the lymph node (14). Because CD169 macro-
phages are known to degrade VSV proteins and prevent viral
dissemination (20), we examined the possibility that these
might be the cells that trap and retain VSV gRNA long-term.
MATERIALS AND METHODS
Viruses and inoculum. Recombinant wild-type VSV (rwtVSV) and VSV-CT1
(114) were grown on BHK-21 cells (ATCC) in Dulbecco’s modified Eagle’s
medium (DMEM) containing 5% fetal bovine serum (FBS) and penicillin-strep-
tomycin (PS; 100 U/ml). VSVG was grown and titrated on BHK-G cells as
previously described (33).
Inoculation of mice. Eight-week-old BALB/c mice were obtained from Charles
River Laboratories and kept for at least 1 week prior to inoculation. Mice were
housed in microisolator cages in a biosafety level 2-equipped animal facility.
Immediately prior to inoculation, all recombinants were diluted in serum-free
DMEM. For intranasal inoculation, mice were lightly anesthetized and inoculum
containing 5  105 PFU was administered in 25 l to the tip of the nose. For
* Corresponding author. Mailing address: Department of Pathology,
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intramuscular inoculation, mice were injected in the right hind leg with 5  105
PFU in 50 l. The Institutional Animal Care and Use Committee of Yale
University approved of all animal experiments done in this study.
Recovery of infectious virus from tissue and plaque assay. Mice were eutha-
nized via an anesthetic overdose. Lungs, spleens, and liver were harvested, rinsed
in sterile phosphate-buffered saline (PBS), and placed in sterile, preweighed 2-ml
Nunc cryotubes. Also, muscle from the hind legs and popliteal, inguinal, and iliac
lymph nodes were collected and placed in cryotubes. Cervical lymph nodes along
the dorsolateral side of the neck, specifically, the mandibular, accessory mandib-
ular, and superficial parotid lymph nodes, were also collected and placed in Nunc
cryotubes. The tissues were weighed in the tubes, dropped in liquid nitrogen, and
later transferred to 80°C for storage. Organs were thawed on ice, suspended in
500 l of DMEM containing 2.5% FBS and PS, and homogenized with Dounce
homogenizers. Homogenates were centrifuged in an Eppendorf centrifuge for 3
min at 12,000 rpm, and the supernatants were frozen at 80°C. To determine
viral titers, supernatants and plasma samples were thawed and plaque assays
were performed as previously described (26).
Reverse transcription, real-time PCR assays. Copy numbers of gRNA from
tissues were determined as described previously using standards of gRNA in-
cluded with each experiment. (34). To determine VSV N mRNA copy number,
an oligo(dT) column purified mRNA standard was prepared from an in vitro
transcription reaction as previously described (28). The number of N transcripts
in the sample was calculated using the N transcript molecular weight and the
percentage of total VSV transcripts that correspond to N mRNA, as previously
determined (11). Next, two-step reverse transcription-PCRs (RT-PCRs) were
performed using the TaqMan reverse transcription reagent kit and Universal
PCR Master Mix (Applied Biosystems). A standard curve for calculation of
mRNA copy numbers was generated using reverse transcription reaction mix-
tures that contained 102, 103, 104, 105, 106, 107, or 108 copies of N mRNA and 1
g carrier tRNA (VWR, West Chester, PA). This standard curve was included
in every experiment.
RNA was isolated from tissue using the Qiagen RNeasy minikit (Valencia,
CA), and 1 g of RNA was reverse transcribed using the tagged primer (5-gg
cagtatcgtgaattcgatgcT19CATAT-3 [lowercase letters indicate the tag sequence]).
To ensure that excess primer did not carry over to the PCR, RT products were
treated with exonuclease I (2 U/sample) and incubated for 30 min at 37°C,
followed by 15 min at 70°C. Real-time PCR was performed using the N forward
primer (5-CATGTCACTGCAAGGCCTAAGA-3), tag reverse primer Rev
(5-GGCAGTATCGTGAATTCGATGC-3), and the N probe (5-6-carboxyflu
orescein [FAM]-AGAAGACAATTGGCAAGTATGCTAAGTCAGAATTTG
A-6-carboxytetramethylrhodamine [TAMRA]-3) on an ABI 7500 real-time se-
quence detection system (Applied Biosystems). The number of copies of mRNA
in each experimental sample was calculated from the threshold cycle values
relative to the standard curve. The copy numbers are expressed as mRNA copy
number per 10 mg of tissue.
Liposome-mediated elimination of macrophages in vivo. Mice were depleted
of phagocytic macrophages using clodronate liposomes as described previously
(7). Dichloromethylene-bisphosphonate (clodronate) was a gift of Roche
Diagnostics GmbH, Mannheim, Germany, and was incorporated into lipo-
somes as described previously (36). Mice were lightly anesthetized and then
injected with 50 l of clodronate liposomes or control PBS liposomes in the
right hind footpad.
To verify macrophage depletion, popliteal, inguinal, and iliac lymph nodes
were removed from 8-week-old BALB/c mice that had been treated with clodr-
onate liposomes for 5 days. The nodes were cut into pieces, strained through
nylon mesh, washed with PBS, and resuspended in blocking buffer. Macrophages
were identified using conjugated antibodies specific for CD11b (BD Biosciences,
San Jose, CA) and CD169 (AbD Serotec, Oxford, United Kingdom). Fluores-
cence intensities were measured with an LSRII flow cytometer, and the data
were analyzed using FlowJo software (Tree Star, San Carlos, CA).
RESULTS
VSV vectors are confined to muscle and lymph nodes fol-
lowing intramuscular inoculation. To characterize the replica-
tion of VSV vaccine vectors in vivo following intramuscular
(i.m.) inoculation, we determined the viral loads in hind leg
muscle, popliteal lymph nodes (PLN), inguinal lymph nodes
(ILN), iliac lymph nodes, plasma, spleen, lung, and liver at
various times postinoculation. Only low and variable levels of
infectious rwtVSV and VSV-CT1 were recovered from the
muscle between 12 and 48 h postinoculation (h.p.i.) (Fig. 1A
and C), and the total amount present in the muscle was less
than 2% of the input virus. Infectious virus was no longer
detectable in the muscle by 3 days postinoculation (d.p.i.). In
addition, both viruses were recovered from the popliteal,
inguinal, and iliac lymph nodes, which are the lymph nodes that
drain the hind leg muscle. In the PLN, virus titers were highest
at 12 h.p.i. and then fell to undetectable levels by 3 d.p.i. (Fig.
1B and D). Similar data were obtained for inguinal and iliac
lymph nodes (not shown). No infectious virus was recovered
from plasma or other peripheral organs or from lymph nodes
on the left side of the animal, opposite the site of inoculation.
To determine if any replication of virus was occurring in the
animals, we calculated the total PFU recovered from all har-
vested organs (lungs; spleen; liver; hind leg muscle; popliteal,
inguinal, and iliac lymph nodes; and cervical lymph nodes
along the dorsolateral side of the neck) at 12 h or 24 h. Based
on the average titers recovered, there appeared to be a small
increase in the total amount of infectious virus relative to the
input level for rwtVSV but not for VSV-CT1 (data not shown).
However, these measurements had a very large standard devi-
ation, and thus, we could not conclude that significant viral
replication was occurring. Nevertheless, we could conclude
that the spread of virus was contained to the lymph system
(data not shown). This contrasts sharply with results obtained
after intranasal inoculation, which leads to viremia and spread
of virus to numerous organs, including lung, spleen, and liver
as well as lymph nodes (34).
Genomic RNA levels reveal little viral replication following
i.m. inoculation but long-term persistence of gRNA in lymph
nodes. To examine the extent of replication of VSV vectors in
greater detail, we used a reverse transcription, real-time PCR
FIG. 1. Replication and spread of VSV vaccine vectors following
i.m. inoculation. Eight-week-old BALB/c mice were inoculated i.m.
with 5  105 PFU of rwtVSV (solid squares) or VSV-CT1 (open
triangles). Viral titers were determined at the times indicated from the
hind leg muscle (A and C) and popliteal lymph node (B and D) as
described in Materials and Methods. Each point represents an indi-
vidual animal. Each bar represents the mean value for all animals at
that time point. The number of points indicates the number of animals
(typically four) tested at each time.
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assay (34) to detect and quantify VSV genomic RNA (gRNA)
sequences. This assay also allowed us to detect the single-cycle
vector VSVG, which does not produce infectious virus and,
therefore, cannot be detected by plaque assay.
The total number of rwtVSV genomes present was less than
the input level at 12 h.p.i. and only slightly higher than the
input level at 24 h.p.i., suggesting little replication even for the
rwt vector (Table 1). In contrast, the total VSV-CT1 and
VSVG genome copy numbers were less than input copy num-
bers at both 12 h.p.i. and 24 h.p.i. (Table 1). Although the same
virus titer was used for each inoculation, the ratio of input
gRNA to PFU was much higher for the latter two vectors
(Table 1), and thus, the higher input might obscure any pos-
sible increase due to replication.
The levels of gRNA from all three vectors were maximal in
the muscle at 12 h.p.i., dropped approximately 100-fold by
3 d.p.i., and were mostly undetectable by day 10 (Fig. 2A, C,
and E). Within the PLN (and other nodes examined; data not
shown), the peak concentrations of gRNA were much higher,
typically about 1  1010 copies/10 mg (Fig. 2B, D, and F),
consistent with the higher viral titers found in lymph nodes.
Between 12 h.p.i. and 3 d.p.i., gRNA levels dropped 100- to
1,000-fold in the PLN. gRNA was still detectable in the PLN,
even at 60 d.p.i., for the VSV-CT1 and VSVG vectors but not
for the rwt vector. Within the iliac and inguinal nodes VSVG
gRNA levels from all mice were also above background at
60 d.p.i. (data not shown). The basis for this greater persis-
tence of VSV-CT1 and VSVG gRNA is not known, but it
could in part be due to the higher gRNA/PFU ratio in the CT1
and G stocks than in the rwt stock (Table 1). Also, any cells
infected with the VSVG virus would be expected to produce
noninfectious particles that might be trafficked differently from
infectious particles.
We also attempted to detect gRNA in blood and other
peripheral organs. We were able to detect a transient appear-
ance of a low level of gRNA from all three vectors in the spleen
of about half of the animals, although we never detected in-
fectious virus in plasma, lung, or liver.
A VSV N mRNA-specific real-time PCR assay to detect VSV
replication. Previously, we have shown that VSV gRNA per-
sists in the draining lymph nodes for at least 60 days after
intranasal (i.n.) inoculation of rwtVSV and VSV-CT1 viruses
(34). Similar persistence was seen here after i.m. inoculation.
To determine if the persistence of gRNA was caused by a low
level of ongoing replication or by retention of inactive gRNA
sequences, we developed a quantitative VSV N mRNA-spe-
cific reverse transcription, real-time assay. If ongoing replica-
tion were occurring, it would require synthesis of N mRNA
and protein (22), and therefore, this assay serves as a surrogate
assay for VSV replication.
To eliminate problems of RNA self-priming that cause a
lack of strand specificity, we adopted the tagged-primer ap-
proach that was first applied to specifically detect hepatitis C
virus positive- and negative-strand RNAs (6). We generated a
VSV N mRNA-specific primer tagged at its 5 end with a
nucleotide sequence unrelated to VSV (5-ggcagtatcgtgaattcg
atgcT20CATAT-3; unrelated sequence shown in lowercase).
To generate a standard curve for quantification of N mRNA,
this primer was used to prime cDNA synthesis from VSV N
TABLE 1. Input virus titers, gRNA levels, and recovered gRNA
Vector Input PFUa Input gRNAb
Recovered gRNAc
12 h 24 h
rwtVSV 5 105 6.5  109 5.7  109  3.2  109 1.16  1010  3.4  109
VSV-CT1 5 105 2.8  1010 1.5  1010  4.0  109 6.6  109  1.14  109
VSVG 5  105 1.6  1011 1.2  1010  3.5  109 6.52  109  2.4  109
a Number of PFU injected.
b Number of gRNA copies injected.
c Extrapolated total of gRNA copies recovered from all tissues harvested  1 standard deviation (n  3 or 4).
FIG. 2. Persistence of VSV gRNA following i.m. inoculation.
Eight-week-old BALB/c mice were inoculated with 5  105 PFU of
rwtVSV (solid squares) (A and B), VSV-CT1 (open triangles) (C and
D), and VSVG (solid circles) (E and F). Leg muscle and popliteal
lymph nodes (PLN) were harvested at the indicated times postinocu-
lation. RNA was isolated from the tissue, and a reverse transcription,
real-time PCR assay was performed to quantify gRNA. Each point
represents the result from an individual animal. Copy numbers below
1 104 copies (background of the assay) are all indicated arbitrarily as
100. Each bar represents the mean value for all animals at that time
point.
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mRNA made in vitro (11). The real-time PCR was then carried
out using a VSV N-specific primer (forward) and a primer
corresponding exactly to the tag sequence. This procedure
ensures that only cDNA generated from the tagged primer is
amplified in this step and eliminates amplification of DNA
made by RNA self-priming (Fig. 3). The assay was specific for
positive-strand (VSV N mRNA) sequences, as it gave no back-
ground signal even after reverse transcription and 50 cycles of
amplification using high levels (108 copies) of purified nega-
tive-strand gRNA template. In contrast, when we used purified
gRNA and either no DNA primer or an untagged 5-
T20CATAT primer in the reverse transcription reaction fol-
lowed by real-time PCR using two internal N primers, there
was a high-level false-positive signal for VSV mRNA.
VSV transcription is not detected later than 3 to 10 days
after i.m. inoculation. We next used the mRNA-specific assay
to determine how long VSV transcription persisted after i.m.
inoculation with VSV vectors. Within the muscle, VSV N
mRNA levels for all three vectors peaked at 12 h.p.i. (Fig. 4A,
C, and E). For rwtVSV and VSVG, these levels were gener-
ally lower than the level of genomic RNA detected at this time,
probably reflecting the high level of input genomes derived
from noninfectious VSV particles (Table 1). In contrast, VSV-
CT1 mRNA levels at 12 h.p.i. are much higher than those of
the other two vectors (Fig. 4C). Yet, the N mRNA transcripts
from all VSV vectors were undetectable in the leg muscle
between 3 and 10 d.p.i. (Fig. 4A, C, and E).
For all three vectors, approximately 107 N mRNA copies/10
mg were found in the PLN at 12 h.p.i. (Fig. 4B, D, and F).
These levels increased for both rwt and CT1 vectors over the
next 12 h, while VSVG N mRNA levels remained constant or
dropped. N mRNA transcripts from rwtVSV were not detect-
able by 3 d.p.i., and VSV-CT1 mRNA sequences were unde-
tectable by 10 d.p.i. VSVG transcripts were also undetectable
in the PLN by 3 d.p.i. Similar data were obtained from inguinal
and iliac lymph nodes (not shown). Thus, the kinetics of clear-
ance of VSV mRNA was relatively rapid, similar to the clear-
ance of infectious virus and far more rapid than clearance of
gRNA. These results indicate that the persistence of gRNA is
not due to ongoing viral replication but rather to trapping of
gRNA.
Lack of persistence of VSV N mRNA after intranasal inoc-
ulation. In our earlier studies of VSV vector replication and
spread following i.n. inoculation, we found long-term persis-
tence (	60 days) of VSV gRNA from rwtVSV, VSV-CT1, and
VSVG in the cervical lymph nodes but not in the lungs. To
examine persistence of VSV transcription in mice inoculated
by this route, the lungs and cervical lymph nodes were har-
vested at various times postinoculation with the three vectors.
For rwtVSV, we found peak levels of about 1  108 N mRNA
copies/10 mg in the lungs and 2  109 N mRNA copies/10 mg
within the lymph nodes (Fig. 5A and B). However, VSV N
mRNA was undetectable in the majority of animals by day 20
and was undetectable in all animals by day 60. N mRNA
sequences from both CT1 and G vectors were initially
present in lung and lymph nodes, but they also became unde-
tectable between 10 and 20 d.p.i. (data not shown). Thus, even
after i.n. inoculation, where VSV replication and spread are
more vigorous, there is no evidence for long-term persistence
of VSV replication.
Role of lymph node macrophages in trapping and persis-
tence of VSV gRNA. Recent studies have shown that CD169
sinusoidal macrophages in the mouse PLN can efficiently trap
VSV particles that are injected into the footpad (14). To ex-
FIG. 3. Diagram of tagged-primer assay specific for positive-strand
VSV N mRNA. The first 5 nucleotides at the 3 end of the tagged
primer (boxed) are complementary to the VSV N mRNA just preced-
ing the poly(A) tail and not to other VSV mRNAs. The lowercase
sequence following the T19 tract is the unrelated sequence tag. cDNA
generated with this primer is then amplified with a VSV N internal
primer, a primer corresponding only to the tag sequence, and a labeled
probe, as described in Materials and Methods.
FIG. 4. Lack of persistence of VSV N mRNA following i.m. inoc-
ulation. Eight-week-old BALB/c mice were inoculated with 5  105
PFU of rwtVSV (solid squares) (A and B), VSV-CT1 (open triangles)
(C and D), or VSVG (solid circles) (E and F). Leg muscle and
popliteal lymph nodes (PLN) were harvested at the indicated times
postinoculation, RNA was prepared from the tissues, and N mRNA
was quantified using the tagged-primer method. The graph shows the
number of mRNA copies per 10 mg of tissue, with each point repre-
senting an individual animal. Copy numbers below 1  104 copies
(background of the assay) are all indicated arbitrarily as 100. Bars
represent the mean values.
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amine the role that macrophages might play in retention and
persistence of VSV gRNA in the PLN following i.m. inocula-
tion, macrophages were depleted from the PLN by injection of
clodronate liposomes into the footpad (8). As shown in Fig.
6A, the depletion of the CD11b CD169 macrophages was
	98% effective.
Depleted and control mice were inoculated i.m. with
rwtVSV and sacrificed at 6 h postinoculation, and VSV gRNA
copy numbers in the PLN were determined (Fig. 6B and C).
The data showed a significant decrease of about 10-fold (P 

0.007, two-tailed unpaired t test) in the gRNA levels as a result
of the depletion (Fig. 6B). Because the macrophage depletion
was greater than 98% effective, the 10-fold reduction in gRNA
at 6 h.p.i. suggests that macrophages were the major, but prob-
ably not the only, cells trapping VSV gRNA at 6 h.p.i. This
result is in agreement with previous studies employing footpad
injection of VSV where titers of virus recovered from the PLN
were reduced 10-fold in depleted animals compared to control
animals (14).
To determine if macrophages were responsible for longer-
term retention of VSV gRNA, we performed depletions on
animals at 5 d.p.i. with VSV vectors and then measured gRNA
levels at 10 d.p.i. when depletion was complete. Although there
was a decrease in the average gRNA levels for both rwtVSV
and VSVG vector levels following depletion (Fig. 6C and D),
there was also a wide range in the values among the animals,
and the differences were not statistically significant.
To investigate persistence at even later times, mice were
inoculated with VSVG, depleted of macrophages at 50 d.p.i.,
and then tested for gRNA levels at 60 d.p.i. This experiment
was performed only on animals infected with the VSVG virus
because this vector gave consistently high levels of gRNA re-
tention at 60 d.p.i. in the PLN (Fig. 2). The results (Fig. 6E) did
not show a significant decrease in gRNA levels following de-
pletion, indicating that macrophages are not the major reser-
voirs of VSVG gRNA at late times. We also verified that the
macrophages were still absent at 10 days after depletion (data
not shown).
DISCUSSION
Live-attenuated and single-cycle VSV-based experimental
vaccine vectors have been used extensively to generate robust
immune responses in a variety of species. In previous studies,
we showed extensive replication and spread of rwtVSV and
attenuated vectors to multiple organs following intranasal in-
oculation, while the single-cycle vectors were very limited in
spread. The extent of spread correlated directly with the ability
of the vectors to induce immune responses when given by this
route (23). In addition, we reported long-term persistence of
vector gRNA in lymph nodes.
FIG. 5. Lack of persistence of VSV N mRNA following i.n. inoc-
ulation. Eight-week-old BALB/c mice were inoculated with 5  105
PFU of rwtVSV. Lungs (A) and cervical lymph nodes (LN) (B) were
harvested at various times postinoculation, RNA was prepared from
the tissues, and N mRNA was quantified using the tagged-primer
method. The graph shows the number of mRNA copies per 10 mg of
tissue, with each point representing values determined from an indi-
vidual animal. Copy numbers below 1 104 copies (background of the
assay) are all indicated arbitrarily as 100. Bars represents the mean
values.
FIG. 6. Effects of lymph node macrophage depletion on trapping of
gRNA. (A) Representative flow cytometry plots of PLN cells stained
with anti-CD11b and anti-CD169 at 5 days following injection of con-
trol PBS liposomes or clodronate liposomes into the footpad. The
numbers circled are the percentages of cells that were CD11b
CD169 in the PLN. (B) VSV gRNA levels in the PLN of control or
macrophage-depleted mice at 6 h after i.m. injection with 3.5  107
PFU of rwtVSV. Depletions were performed 5 days prior to injection.
(C and D) VSV gRNA levels in the PLN of mice that were inoculated
i.m. with 3.5 107 PFU of rwtVSV (C) or VSVG (D). Five days after
inoculation, PLN macrophages were depleted with clodronate lipo-
somes, and the levels of gRNA in the PLN of control or depleted mice
were measured 5 days later (10 d.p.i.). (E) VSV gRNA levels in the
PLN of mice that were inoculated i.m. with 3.5  107 PFU of VSVG.
Fifty days after inoculation, PLN macrophages were depleted with
clodronate liposomes, and the levels of gRNA in the PLN of control or
depleted mice were measured 10 days later (60 d.p.i.). Control
experiments showed that macrophage depletion was still complete
at 10 days after clodronate treatment. Each point represents the
gRNA level determined from an individual animal. Bars represent
the mean values.
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In the current study focusing on i.m. inoculation, we deter-
mined that the rwtVSV, replication-attenuated, and single-
cycle VSV vectors were all trafficked efficiently from the site of
injection in the muscle to lymph nodes but were not propa-
gated to other tissues. Our finding of similar peak levels of
gRNA in the lymph nodes for all vectors likely explains the
ability of the attenuated and single-cycle vectors to generate
immune responses comparable to those for rwtVSV vectors
when given by this route (23). The efficient trafficking of the
single-cycle vector to the lymph node indicates that production
of new infectious virus and subsequent rounds of infection are
not required for this trafficking. Our results are consistent with
a recent study showing that VSV particles made replication
defective with UV light are efficiently trafficked to and trapped
in lymph nodes after injection into the mouse footpad (14).
VSV vectors do not replicate extensively in the muscle tissue
and are most likely carried through the lymphatics and con-
centrated in the draining lymph nodes where effective antigen
presentation and stimulation of immune responses occur. Our
data indicate also that little replication of VSV occurred in the
lymph nodes because the total gRNA recovered from the
nodes was similar to the input gRNA level.
We have previously seen long-term persistence of VSV
gRNA within draining lymph nodes after i.n. inoculation (34).
Long-term persistence of VSV RNA in cattle and hamsters has
also been reported elsewhere (1, 18). A recent study has also
reported the concentration in lymph nodes and long-term per-
sistence of rwt and other attenuated VSV vector RNAs after
i.m. inoculation of mice (12).
The most interesting question related to the persistence of
vector gRNA is the mechanism. We suggested previously that
the gRNA persistence could be due either to low-level, long-
term VSV replication that is refractory to clearance by the
immune system or to sequestration of inactive gRNA se-
quences (34). Long-term persistence of VSV-encoded antigen
has also been reported elsewhere (35), but the mechanism of
antigen persistence is not known. Because we found persis-
tence of gRNA even in mice infected with the single-cycle,
VSVG vector, we could exclude any requirement for multiple
rounds of infection to maintain persistence. We believe that
persistence of VSV-encoded antigen for 6 weeks (35) is prob-
ably occurring in the absence of VSV replication. Nonetheless,
we could not exclude the possibility that VSVG vectors might
be able to replicate long-term in some cells without causing cell
death.
To determine definitively if VSV replication was persistent,
we developed a VSV mRNA assay specific for the most abun-
dant VSV mRNA encoding the VSV N protein. VSV replica-
tion requires continuing VSV mRNA and protein synthesis,
and thus, the absence of mRNA would indicate absence of
replication (22). Similar to gRNA, we found that VSV N
mRNA transcripts appeared soon after infection in the ani-
mals. But, unlike gRNA, VSV N mRNA did not persist beyond
4 to 10 days postinfection after i.m. inoculation or beyond
20 d.p.i. following i.n. inoculation. The levels of mRNA de-
tected were less than the levels of gRNA, probably indicating
that few of the gRNA molecules were involved in transcription
and replication and thus were likely derived from noninfec-
tious input virions. Our data indicate that the gRNA detected
over the long term is not involved in replication and is probably
sequestered somewhere in the lymph node, perhaps in the
form of RNase-resistant nucleocapsids. The lack of detectable
long-term VSV vaccine vector replication in vivo minimizes
concerns about accumulation of mutations in live-attenuated
vectors that could potentially lead to increased vector viru-
lence.
The elegant studies by Junt et al. have shown that CD169
lymph node macrophages are critical for binding and trapping
of VSV virions (14). Furthermore, translocation of VSV anti-
gen to B and T cells occurs shortly after entering the lymph
node (10, 14). Our results using macrophage depletion from
lymph nodes are consistent with initial trapping of VSV gRNA
by CD169 lymph node macrophages but indicate that the
majority of the long-term persistence of VSV gRNA in lymph
nodes is not occurring in these cells.
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